Reviva Pharmaceuticals Q2 EPS $(0.55) Misses $(0.28) Estimate
Portfolio Pulse from Benzinga Newsdesk
Reviva Pharmaceuticals reported Q2 losses of $(0.55) per share, missing the analyst consensus estimate of $(0.28) by 96.43%. This represents a 89.66% increase in losses compared to the same period last year.
August 14, 2023 | 8:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Reviva Pharmaceuticals' Q2 earnings were significantly below analyst estimates, with losses per share increasing by 89.66% compared to the same period last year.
Reviva Pharmaceuticals reported a significant miss on its Q2 earnings, with losses per share almost double the analyst consensus estimate. This is likely to negatively impact investor sentiment and could lead to a short-term decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100